Innovent Biologics (HK:1801) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innovent Biologics has received approval from China’s National Medical Products Administration for its drug Dovbleron, a next-generation treatment for ROS1-positive non-small cell lung cancer. This marks the 13th addition to Innovent’s portfolio, highlighting the company’s commitment to innovative cancer therapies. The approval follows positive results from a pivotal Phase 2 trial, showcasing significant efficacy in patients.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.